# US 2008/0188405 A1 · Cancer Markers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188405 A1
- Document ID: US20080188405A1
- Status: Published application
- Kind: A1
- Application number: 11/664,137
- Filed: 2005-09-20
- Published: 2008-08-07
- Earliest claimed: 2004-09-30
- Assignees: IFOM Fondazione Instituto FIRC di Oncologia Molecolare
- Inventors: Pier Paolo Di Fiore; Salvatore Pece; Ian Marc Bonapace; Francesco Nicassio; Fabrizio Bianchi; Manuela Vecchi; Stefano Confalonieri
- Web page: https://patentgrep.com/patent/US20080188405A1

## CPC

- G01N 33/57515: of the breast
- A61P 35/00: Antineoplastic agents
- G01N 2333/723: Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention related to methods of diagnosis and prognosis of cancer, the methods comprising determining the level of one or more gene products. In addition, the invention relates to modulators of the gene products for use in treatment of cancer. The genes include EIA-induced genes and Numb.

## Claims

### Claim 1

A method of providing an indicator for assessment of cancer in a patient, the method comprising:
providing an assay sample of tissue obtained from said patient; and
determining the Numb status of said sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein determining the Numb status of said sample comprises determining the level of Numb protein in said sample.

### Claim 3 (depends on 2)

The method of claim 2, wherein the method further comprises comparing said level to a level of said protein in a control sample of cells.

### Claim 4

The method of any one of the preceding claims, wherein the cancer is breast cancer.

### Claim 5

The method of any one of the preceding claims wherein the method further comprises determining the status in the assay sample of one or more further proteins which are associated with prognosis or diagnosis of the cancer.

### Claim 6 (depends on 5)

The method of claim 5, which comprises determining the ER (estrogen receptor) and/or p53 status in the assay sample.

### Claim 7

The method of any one of the preceding claims, which further comprises determining the level of Notch activity in said sample.

### Claim 8

The method of any one of the preceding claims, wherein the method further comprises determining the expression level of one or more genes which is transcriptionally regulated by Notch.

### Claim 9

A kit for use in the assessment of cancer, the kit comprising a specific binding partner for a Numb gene expression product, and a specific binding partner for at least one other gene expression product associated with prognosis or diagnosis in the cancer.

### Claim 10 (depends on 9)

The kit of claim 9, wherein the kit comprises a specific binding partner for a p53 and/or ER gene expression product.

### Claim 11

A kit for the assessment of cancer comprising a specific binding partner of a Numb gene expression product, wherein said binding partner is immobilised on a solid support.

### Claim 12

Use a specific binding partner of a Numb expression product for the manufacture of a kit for the assessment of cancer in a patient.

### Claim 13 (depends on 9, 10, 11)

The use of claim 11, wherein the kit is a kit according to any one of claims 9 to 11.

### Claim 14 (depends on 11, 12, 13)

The kit of claim 11 or the use of claim 12 or 13, wherein the assessment is the diagnosis or prognosis of cancer

### Claim 15 (depends on 11, 12, 13)

The kit of claim 11 or the use of claim 12 or 13, wherein the assessment is determination of the susceptibility of a tumour in a patient to treatment with an inhibitor of Notch signalling.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The kit or use of any one of claims 11 to 15 wherein the cancer is breast cancer.

### Claim 17 (depends on 11, 12, 13, 14, 15, 16)

The kit or use of any of claims 11 to 16 wherein the Numb expression product is a Numb protein.

### Claim 18 (depends on 17)

The kit or use of any of claim 17, wherein the specific binding partner for Numb protein is an antibody.

### Claim 19 (depends on 18)

The kit or use of claim 18, wherein the antibody is monoclonal.

### Claim 20

A method of determining susceptibility of a tumour in a patient to treatment with an inhibitor of Notch signalling, the method comprising:
providing an assay sample of tumour tissue obtained from said patient; and
determining the Numb status of said sample.

### Claim 21 (depends on 20)

The method of claim 20, wherein determining the Numb status of said assay sample comprises determining the level of Numb protein in said sample.

### Claim 22 (depends on 21)

The method of claim 21, wherein the method further comprises comparing said level to a reference level obtained from a control sample.

### Claim 23 (depends on 20, 21, 22)

The method of any one of claims 20 to 22 wherein the cancer is breast cancer.

### Claim 24 (depends on 20, 21, 22, 23)

The method of any one of claims 20 to 23 further comprising administering an inhibitor of Notch signalling to said patient.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The method of any one of claims 20 to 24, further comprising measuring Notch activity in a sample obtained from a patient prior to and subsequent to the administration of said inhibitor.

### Claim 26 (depends on 25)

The method of claim 25 wherein measuring Notch activity comprises measuring the expression level of at least one gene whose expression is regulated by Notch.

### Claim 27

Use of an inhibitor of Notch signalling in the manufacture of a medicament for the treatment of cancer in a patient, wherein said patient has reduced Numb activity in a tumour relative to a control sample.

### Claim 28 (depends on 27)

The use of claim 27, wherein said patient has reduced levels of Numb protein relative to a control sample.

### Claim 29 (depends on 27, 28)

The use of claim 27 or claim 28 wherein the cancer is breast cancer.

### Claim 30 (depends on 20, 27, 28, 29)

The use of any one of claims 27 to 29 wherein said patient has been subject to a method according to claim 20.

### Claim 31

A method of screening for a candidate agent for the treatment of cancer in a patient, comprising:
providing a test system comprising a Numb polypeptide and an enzyme capable of targeting Numb for degradation;
contacting said test system with a test agent;
and assessing the ability of the test agent to inhibit the targeting of Numb for degradation.

### Claim 32

A method of selecting a specific binding partner of a gene expression product for use in providing an indicator for the assessment of cancer, comprising:
identifying a gene whose expression is modulated by contacting a terminally differentiated mammalian cell in culture with an agent which causes re-entry of the cell into the cell cycle; and
selecting a specific binding partner for an expression product of said gene.

### Claim 33 (depends on 32)

A method according to claim 32 wherein said gene has modulated expression in a mammalian tumour.

### Claim 34 (depends on 32, 33)

The method of claim 32 or claim 33, wherein the agent is E1A.

### Claim 35 (depends on 32, 33, 34)

The method of any one of claims 32 to 34, wherein the method comprises identifying at least two genes, and selecting specific binding partners of an expression product of at least two genes.

### Claim 36 (depends on 35)

The method of claim 35, wherein the method comprises identifying at least two genes
a) whose expression is modulated by contacting a cell in culture with an E1A protein so as to cause re-entry of the cell into the cell cycle;
b) which belong to the same E1A activated signalling pathway.

### Claim 37 (depends on 36)

The method of claim 36, wherein said at least two genes genes have modulated expression in a mammalian tumour.

### Claim 38 (depends on 32, 37)

The method of any one of claims 32 to claim 37, wherein the method comprises identifying at least one gene whose expression is not strongly modulated by inactivation of a pocket protein and whose expression is significantly modulated by an E1A pocket binding mutant.

### Claim 39 (depends on 38)

The method of claim 38, wherein the pocket protein is RB.

### Claim 40 (depends on 32, 33, 34, 35, 36, 37, 38, 39)

A method of making a kit for the assessment of cancer, comprising having selected a specific binding partner or partners according to any one of claims 32 to 39, incorporating said binding partner or partners in a kit.

### Claim 41 (depends on 40)

A method according to claim 40 wherein at least 2, 3, 4 or 5 of said genes are incorporated into the kit.

### Claim 42 (depends on 40, 41)

A method according to claim 40 or 41 further comprising incorporation of a nucleic acid sequence suitable for the detection of a transcript of the gene whose expression product is bound by the specific binding partner.

### Claim 43 (depends on 42)

A method according to claim 42 wherein the kit is a gene chip array.

### Claim 44 (depends on 32, 33, 34, 35, 36, 37, 38, 39)

A method of providing an indicator for the assessment of cancer, comprising having selected a specific binding partner or partners according to any one of claims 32 to 39, providing an assay sample of tissue obtained from said patient and determining the level of at least one gene expression product by determining binding to the selected binding partner or binding partners.

### Claim 45 (depends on 44)

The method of claim 44, further comprising comparing the level so determined with the level of said expression product in a control sample of cells.

### Claim 46

A method of providing an indicator for assessment of cancer in a patient, the method comprising:
providing an assay sample of tissue obtained from said patient;
determining the level in the sample of an expression product of at least one gene selected from DDX21, SF3B1, ch-TOG, SKIN, TRPC4AP and SMU-1, or other genes listed in FIG. 11.

### Claim 47 (depends on 46)

The method of claim 46, further comprising comparing the level so determined with the level of said expression product in a control sample of cells.

### Claim 48 (depends on 46, 47)

The method of claim 46 or 47, wherein the cancer is breast cancer and the method comprises determining the level of expression product in the sample of one or more of ch-TOG, SKIN, and TRPC4AP.

### Claim 49 (depends on 46, 47)

The method of claim 46 or 47, wherein the cancer is colon cancer, and the method comprises determining the level of expression product in the sample of one or more of SKIN, SMU-1 and ch-TOG.

### Claim 50

A method of providing an indicator for assessment of breast cancer in a patient comprising:
providing an assay sample of tissue obtained from said patient; and
determining the level in said sample of an expression product of at least one gene from table 2.

### Claim 51

A method of providing an indicator for assessment of NSCLC in a patient comprising:
providing an assay sample of tissue obtained from said patient; and
determining the level in said sample of an expression product of at least one gene from table 3 or table 4.

### Claim 52 (depends on 50, 51)

The method of claim 50 or claim 51 comprising determining the level in said sample of an expression product of at least 2, 3, 4 or 5 of said genes from the table.

### Claim 53 (depends on 50, 51, 52)

The method of any one of claims 50 to 52, further comprising comparing the level so determined with the level of said expression product in a control sample of cells.

### Claim 54

A kit for use in the assessment of cancer, wherein the kit comprises a specific binding partner for the expression product of:
at least one gene selected from DDX21, SF3B1, ch-TOG, SKIN, TRPC4AP and SMU-1, or other gene listed in FIG. 11; or
at least one of ch-TOG, SKIN, and TRPC4AP;
at least one of SKIN, SMU-1 and ch-TOG; or
at least one gene from table 2; or
at least one gene from table 3 or table 4,
wherein said specific binding partner is immobilised on a solid surface.

### Claim 55 (depends on 54)

The kit of claim 54 which comprises a specific binding partner for the expression product of at least 2, 3, 4 or 5 genes from table 2, table 3 or table 4.

### Claim 56 (depends on 54, 55)

The kit of claim 54 or claim 55 which comprises a nucleic acid sequence suitable for the detection of a transcript of said gene or genes.

### Claim 57 (depends on 56)

The kit of claim 56 which is a gene chip array.

### Claim 58

Use of a specific binding partner of:
a gene selected from DDX21, SF3B1, ch-TOG, SKIN, TRPC4AP and SMU-1, or other gene listed in FIG. 11; or
a gene selected from table 2; or
a gene selected from table 3 or table 4, in the manufacture of a kit for use in providing an indicator for the assessment of cancer.

### Claim 59

A method of screening for a candidate agent for the treatment of cancer in a patient, comprising:
a) providing a protein selected from DDX21, SF3B1, ch-TOG, SKIN, TRPC4AP and SMU-1 or other gene listed in FIG. 11, or a protein of table 2, table 3 or table 4;
b) bringing the protein into contact with a test agent;
c) determining whether said test agent is capable of binding and/or modulating the activity of the protein.

### Claim 60

A method of screening for a candidate agent for the treatment of cancer in a patient, comprising:
identifying a gene whose expression is modulated in a terminally differentiated mammalian cell in culture by contacting the cell with an agent which causes its re-entry into the cell cycle;
providing a protein expressed by the gene;
bringing the protein into contact with a test agent; and
determining whether said test agent is capable of binding and/or modulating the activity of the protein.

### Claim 61 (depends on 60)

A method according to claim 60 wherein the expression of said gene is not strongly modulated by inactivation of a pocket protein, and is significantly modulated by an E1A pocket binding mutant.

### Claim 62 (depends on 60, 61)

A screening method according to claim 60 or claim 61, wherein the agent which causes re-entry into the cell cycle is E1A.

### Claim 63 (depends on 59, 60, 61, 62)

A screening method according to any one of claims 59 to 62, wherein said test agent is an antibody or binding fragment thereof which binds said protein.

### Claim 64 (depends on 59, 60, 61, 62)

A screening method according to any one of claims 59 to 62, wherein said test agent is a fragment of said protein or a mimetic thereof.

### Claim 65

A method of screening for a candidate agent for the treatment of cancer in a patient, wherein said method comprises
a) providing a transformed cell in culture;
b) bringing said cell into contact with a test agent and
c) determining whether said test agent is capable of modulating the level of a transcript selected from DDX21, SF3B1, CH-TOG, SKIN, TRPC4AP and SMU-1 or other transcripts listed in FIG. 11 or a transcript of table 2, table 3 or table 4.

### Claim 66

A method of screening for a candidate agent for the treatment of cancer in a patient, comprising:
identifying a gene whose expression is modulated in a terminally differentiated mammalian cell in culture by contacting the cell with an agent which causes its re-entry into the cell cycle;
providing a transformed cell in culture:
bringing said cell into contact with a test agent;
determining whether said test agent is capable of modulating the level of the transcript of said gene.

### Claim 67 (depends on 60, 66, 67)

A method according to claim 60 wherein the expression of said gene is not strongly modulated by inactivation of a pocket protein, and is significantly modulated by an EIA pocket binding mutant. A screening method according to claim 66 or claim 67, rein the agent which causes re-entry into the cell cycle is

### Claim 68 (depends on 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

A screening method according to any one of claims 66 to wherein said test agent is an antisense oligonucleotide or RNAi. Use of an agent obtainable in a screening method of any of claims 59 to 69 for the manufacture of a medicament for treatment of cancer.
